Biogen said Leqembi logged its best quarter since launch, following strong global sales momentum. The company reported $184 million in global sales for Leqembi in the second quarter and raised or confirmed its outlook, reinforcing investor focus on sustained adoption of anti-amyloid therapy as uptake continues. The update comes as Biogen works to stabilize growth after earlier launch-phase volatility and compete within an evolving Alzheimer’s disease treatment landscape.